Kahn Brothers Group’s Novartis NVS Stock Holding History

Kahn Brothers Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.07M	Sell	13,186 -200	-1%	-$30K	0.33%	20
2026 Q1	$2.04M	Sell	13,386 -292	-2%	-$44.8K	0.36%	20
2025 Q4	$1.89M	Sell	13,678 -648	-5%	-$84.9K	0.33%	20
2025 Q3	$1.84M	Sell	14,326 -4,145	-22%	-$506K	0.35%	19
2025 Q2	$2.24M	Sell	18,471 -3,438	-16%	-$388K	0.45%	17
2025 Q1	$2.44M	Buy	21,909 +728	+3%	+$77.5K	0.49%	16
2024 Q4	$2.06M	Buy	21,181 +3,600	+20%	+$384K	0.45%	17
2024 Q3	$2.02M	Hold	17,581	–	–	0.35%	18
2024 Q2	$1.87M	Buy	17,581 +2,168	+14%	+$218K	0.31%	20
2024 Q1	$1.49M	Sell	15,413 -2,650	-15%	-$272K	0.22%	23
2023 Q4	$1.82M	Sell	18,063 -3,515	-16%	-$339K	0.29%	20
2023 Q3	$2.2M	Hold	21,578	–	–	0.34%	18
2023 Q2	$2.18M	Hold	21,578	–	–	0.32%	19
2023 Q1	$1.99M	Hold	21,578	–	–	0.29%	20
2022 Q4	$1.96M	Sell	21,578 -1,500	-6%	-$126K	0.26%	20
2022 Q3	$1.75M	Hold	23,078	–	–	0.27%	20
2022 Q2	$1.95M	Buy	23,078 +700	+3%	+$61.4K	0.26%	20
2022 Q1	$1.96M	Hold	22,378	–	–	0.25%	21
2021 Q4	$1.96M	Buy	22,378 +1,980	+10%	+$164K	0.27%	19
2021 Q3	$1.67M	Hold	20,398	–	–	0.23%	22
2021 Q2	$1.86M	Hold	20,398	–	–	0.27%	23
2021 Q1	$1.74M	Sell	20,398 -2,000	-9%	-$179K	0.27%	23
2020 Q4	$2.12M	Sell	22,398 -300	-1%	-$26.2K	0.37%	19
2020 Q3	$1.97M	Hold	22,698	–	–	0.37%	20
2020 Q2	$1.98M	Sell	22,698 -500	-2%	-$43.2K	0.34%	21
2020 Q1	$1.91M	Sell	23,198 -2,575	-10%	-$230K	0.35%	20
2019 Q4	$2.44M	Hold	25,773	–	–	0.3%	22
2019 Q3	$2.24M	Hold	25,773	–	–	0.28%	22
2019 Q2	$2.35M	Buy	25,773 +391	+2%	+$33.1K	0.29%	22
2019 Q1	$2.19M	Hold	25,382	–	–	0.34%	22
2018 Q4	$1.95M	Sell	25,382 -520	-2%	-$40.5K	0.35%	22
2018 Q3	$2M	Hold	25,902	–	–	0.31%	22
2018 Q2	$1.75M	Buy	25,902 +1,339	+5%	+$92.4K	0.28%	22
2018 Q1	$1.78M	Sell	24,563 -5,134	-17%	-$391K	0.28%	21
2017 Q4	$2.23M	Buy	29,697 +520	+2%	+$39.2K	0.35%	21
2017 Q3	$2.24M	Sell	29,177 -74	-0.3%	-$5.59K	0.34%	22
2017 Q2	$2.19M	Sell	29,251 -1,898	-6%	-$135K	0.33%	22
2017 Q1	$2.07M	Buy	31,149 +938	+3%	+$62.5K	0.36%	21
2016 Q4	$1.97M	Sell	30,211 -639	-2%	-$41.5K	0.33%	22
2016 Q3	$2.18M	Hold	30,850	–	–	0.4%	22
2016 Q2	$2.28M	Hold	30,850	–	–	0.44%	21
2016 Q1	$2M	Hold	30,850	–	–	0.38%	22
2015 Q4	$2.38M	Sell	30,850 -1,004	-3%	-$79.8K	0.43%	22
2015 Q3	$2.62M	Buy	31,854 +446	+1%	+$39.7K	0.49%	21
2015 Q2	$2.77M	Sell	31,408 -3,152	-9%	-$289K	0.47%	21
2015 Q1	$3.05M	Hold	34,560	–	–	0.52%	21
2014 Q4	$2.87M	Buy	34,560 +669	+2%	+$55.5K	0.49%	21
2014 Q3	$2.86M	Buy	33,891 +4,464	+15%	+$361K	0.46%	22
2014 Q2	$2.39M	Sell	29,427 -1,897	-6%	-$149K	0.35%	22
2014 Q1	$2.39M	Buy	31,324 +781	+3%	+$56.9K	0.34%	20
2013 Q4	$2.2M	Sell	30,543 -2,232	-7%	-$155K	0.38%	19
2013 Q3	$2.25M	Sell	32,775 -1,116	-3%	-$73.8K	0.33%	22
2013 Q2	$2.15M	Buy	+33,891	New	+$2.21M	0.33%	23

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kahn Brothers Group's NVS Position: Q2 2026 in Review

Kahn Brothers Group reduced its Novartis (NVS) stake by 1.5% in Q2 2026, selling an estimated $30K and leaving 13,186 shares worth $2.07M. The position accounts for 0.33% of the portfolio, ranked #20.

Kahn Brothers Group first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.05M in Q1 2015. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Kahn Brothers Group held 13,186 shares of Novartis worth $2.07M as of Q2 2026.
Kahn Brothers Group sold 200 Novartis shares in Q2 2026, an estimated $30K.
Novartis made up 0.33% of Kahn Brothers Group's portfolio in Q2 2026, its #20 holding.
Kahn Brothers Group first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
Kahn Brothers Group's Novartis position peaked at $3.05M in Q1 2015.
1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Kahn Brothers Group's 13F filing for Q2 2026, filed 14 Aug 2026.